Medicare Built a GLP-1 Bridge After Insurers Said No — Now the Clock Is Running — type0

Medicare Built a GLP-1 Bridge After Insurers Said No — Now the Clock Is Running — type0 | type0

Medicare launched a two-year workaround Wednesday to cover expensive weight-loss drugs for seniors at $245 a month, with the government absorbing the financial risk itself after every major private insurer declined to participate. The fallback program, called the Medicare GLP-1 Bridge, runs July 1, 2026 through December 31, 2027 and operates outside the standard Medicare prescription drug benefit, with CMS paying pharmacies directly rather than routing payments through private Part D plans, according to CMS. The program activated after the original federal pilot, called BALANCE, collapsed because insurers took one look at the terms and declined.

GLP-1s — a class of injectable and oral drugs that includes Novo Nordisk's Wegovy and Eli Lilly's Zepbound — have been shown to reduce body weight by 15 to 20 percent in clinical trials, making them the most effective pharmacological obesity treatment in decades. A month's supply typically lists at over $1,000. Medicare, the federal health insurance program for Americans 65 and older, was not permitted to cover weight-loss drugs alone until recently.

The Bridge is explicitly temporary. A two-year sunset is built into its structure. CMS is running a controlled experiment, with the agency as sole guarantor, before deciding whether to make coverage permanent. The alternative, the BALANCE model, required Medicare Part D plans covering 80 percent of enrollees to opt in for the pilot to proceed. That condition failed. Aetna declined. UnitedHealth declined. The April 20 deadline passed without the required threshold, according to Public Citizen.

CVS Health, which owns Aetna, declined both programs. UnitedHealth said it would participate in the Bridge demo while declining BALANCE — a split that suggests the underlying math on these drugs remains unsolved even when the government shares the risk.

The $245-a-month price Lilly and Novo set for Medicare and Medicaid stays in place under the Bridge, as does the $50 monthly copay for beneficiaries. What collapsed was the mechanism designed to distribute that cost across private plans. The Bridge substitutes direct government administration instead.

"The insurers said no, so the government is covering the drugs anyway," one health policy consultant said, speaking on background. "That's not a victory for the model. That's the model failing and Washington refusing to take no for an answer."

Peter Maybarduk, access to medicines director at the consumer advocacy group Public Citizen, said the administration had other options it chose not to use. "The government has power under existing law to authorize much more affordable generic competition with patented GLP-1s," Maybarduk said. "Those generics will be available soon across the border for Canadians, but not available to Americans unless the Trump administration acts. Failure to take this power seriously means that Medicare and Medicaid will suffer under mounting costs, and Americans will endure treatment rationing and mounting debt." The quote appears verbatim in a Public Citizen press release.

The structural question the sunset raises is whether CMS is using the Bridge as a genuine pathway to permanent coverage, or as political cover — a way to say GLP-1s were covered while the durable solution gets deferred again. The two-year timeline suggests the agency has not answered that question itself.

Amazon entered the same market the same day the Bridge documentation went live. Through One Medical and Amazon Pharmacy, the company launched a GLP-1 management program offering Wegovy and Eli Lilly's oral GLP-1 Foundayo at $25 a month with insurance, or $149 a month cash-pay. Amazon is vertically integrating primary care, prescription, and delivery without waiting for any insurer's permission. Its program does not yet touch Medicare. But the competitive signal is direct: the moment the government bears the risk for GLP-1 coverage, private companies with integrated health platforms have a cleared runway to offer the same drugs cheaper, faster, and without the administrative complexity of government programs.

The Bridge keeps Medicare seniors covered through 2027. It does not stop Amazon, Hims, or anyone else from building the model that insurers refused to touch.